AZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical Significance

(RTTNews) - Overall survival results from the TROPION-Lung01 phase 3 trial numerically favored Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small https://www.nasdaq.com/articles/azn:datopotamab-deruxtecan-shows-favorable-survival-results-falls-short-of-statistical